The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$775,114 ปริมาณ
Mar 31, 2026
July 31
50%
June 30
1%
December 31
24%
$775,114 ปริมาณ
July 31
$0 ปริมาณ
50%
June 30
$342,494 ปริมาณ
1%
December 31
$167,738 ปริมาณ
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$775,114วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$775,114วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive order, immediately moved FDA-approved marijuana products and state-licensed medical marijuana into Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026 and conclude by mid-July, will examine full reclassification and could produce a final rule in the Federal Register shortly afterward. These steps follow the 2024 proposed rulemaking and represent the most recent concrete acceleration of the Controlled Substances Act process. Traders are therefore focused on whether the compressed hearing timeline and any subsequent rulemaking will resolve the broader question before key year-end or quarterly deadlines, with procedural outcomes and potential litigation remaining the primary variables.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย